# A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

> **NCT02327078** · PHASE1,PHASE2 · COMPLETED · sponsor: **Incyte Corporation** · enrollment: 307 (actual)

## Conditions studied

- B-cell Malignancies
- Colorectal Cancer (CRC)
- Head and Neck Cancer
- Lung Cancer
- Lymphoma
- Melanoma
- Ovarian Cancer
- Glioblastoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Epacadostat
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT02327078
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-26
- **Primary completion:** 2020-06-16
- **Final completion:** 2020-06-16
- **Target enrollment:** 307 (ACTUAL)
- **Last updated:** 2025-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02327078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02327078, "A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02327078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*